Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma

Vonasek, Julia; Edslev, Pernille Wendtland; d’Amore, Francesco; Hasle, Henrik

doi:10.1002/pbc.28082

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, patients with genetic syndromes are generally excluded from clinical trials, 28 generating some concerns in the use of innovative drugs to treat such patients. We reported that treatment with BV at 1.8 mg/kg in association with nivolumab was well tolerated in a patient with Down syndrome, confirming the previously reported experience of a 13‐year‐old female with Down syndrome treated with BV monotherapy at the dose of 1.2 mg/kg without any significant side effect 11 …”

Section: Discussionsupporting

confidence: 88%

“…We reported that treatment with BV at 1.8 mg/kg in association with nivolumab was well tolerated in a patient with Down syndrome, confirming the previously reported experience of a 13-year-old female with Down syndrome treated with BV monotherapy at the dose of 1.2 mg/kg without any significant side effect. 11 The present analysis has some limitations due to the retrospective nature of the study. First, the study design and heterogeneity of the patient cohort did not allow a simple comparison among groups of treatments and disease status at the beginning of BV therapy.…”

Section: Discussionmentioning

confidence: 91%

“…7 Despite the widespread use of BV in adult's oncology and the large number of prospective and retrospective studies, 8,9 there are few data on efficacy and safety in paediatric setting. [10][11][12] Therefore, there are still some concerns about its use in paediatrics, especially in younger patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real‐life study

Massano

Carraro

Mussolin

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Brentuximab vedotin (BV) is an antibody drug-conjugated anti-CD30 approved for the treatment of adult classical Hodgkin's lymphoma (HL), whereas it is considered as off-label indication in paediatrics. The aim of the study was to evaluate the safety and efficacy of BV to treat patients aged less than 18 years with refractory/relapsed HL. Materials and methods:In this multicentre, retrospective study, 68 paediatric patients who received at least one dose of BV between November 2011 and August 2020 were enrolled. A median of nine doses of BV were administered as monotherapy (n = 31) or combined with other therapies (n = 37). BV was administrated alone as consolidation therapy after stem cell transplantation (SCT) in 12 patients, before SCT in 18 patients, whereas in 15 patients it was used before and after SCT as consolidation therapy. Median follow-up was 2.8 years (range: 0.6-8.9 years). Results:The best response was observed in the 86% of patients; the overall response rate was 66%. The 3-year progression-free survival was 58%, whereas the overall survival was 75%. No statistically significant differences between patients treated with BV monotherapy or combination were highlighted. In multivariate analysis, patients with non-nodular sclerosis HL and not transplanted had an increased risk of failure.Overall, 46% of patients had grade 3-4 adverse events that led to BV discontinuation in five of them. Conclusion:In conclusion, our study confirms that BV was a safe and effective drug, able to induce complete remission, either as monotherapy or in association with standard therapy.

show abstract